Dolutegravir + Abacavir + Lamivudine 600/50/300mg
Product Overview
| Generic Name | Dolutegravir + Abacavir + Lamivudine 600/50/300mg |
| Brand Name(s) | Triumeq |
| Category | Antivirals - Antiretrovirals |
| Form | 30 Film-coated oral tablets |
| Strength | 600 mg abacavir / 50 mg dolutegravir / 300 mg lamivudine per tablet |
| Therapeutic Class | Integrase strand transfer inhibitor (dolutegravir) + 2 NRTIs (abacavir, lamivudine) |
| ATC Code | J05AR13 |
Manufacturing & Regulatory
| Manufacturer | ViiV Healthcare; Varios generic mfgs |
| GMP Compliance | WHO-GMP for generics |
| DMF/CEP | type II |
| COFEPRIS | 010.000.6108.00 |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 10 pks |
| Shelf Life | 24 Months |
| Storage | Store below 30°C Protect from moisture and light. Do not refrigerate or freeze. |
| Incoterms | EXW/FOB/CIF negotiable |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| SDS-Safety Data Sheet (PDF) | Upon Request |
| CTD Summary (PDF) | Upon Request |
Special Notes
Indications & Usage: Dolutegravir-Abacavir-Lamivudine combo is indicated for the treatment of HIV‑1 infection in patients (adults/adolescents ≥25 kg), combining an integrase inhibitor plus two NRTIs in a single, once-daily tablet. It reduces HIV viral load and is suitable for both treatment-naïve and experienced patients without resistance.